COMMENTARY
High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
Doctors who specialize in osteoporosis have high hopes for a number of new drugs that are currently in development. Cathepsin K inhibitors, which could debut in the near future, anti-sclerostin antibodies, and parathyroid hormone-related protein (PTHrP) analogs have attracted particular…
To read the full story
COMMENTARY
- FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed
December 9, 2025
- MOF Autumn Proposals Signal a Shift from Drug Pricing to Cost-Sharing Reform
November 17, 2025
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- The Price of Stability: Who Bears Japan’s Drug Distribution Burden?
October 27, 2025
- Inside Eylea - 2: Will a Bio-AG Return after Six Years? Pricing Debate Resumes
October 7, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





